Resistance to
chemotherapy is the primary cause of treatment failure in over 90% of
cancer patients in the clinic. Research in nanotechnology-based therapeutic alternatives has helped provide innovative and promising strategies to overcome multidrug resistance (MDR). By targeting CD44-overexpressing MDR
cancer cells, we have developed in a single-step a self-assembled, self-targetable, therapeutic semiconducting single-walled
carbon nanotube (sSWCNT) drug delivery system that can deliver chemotherapeutic agents to both
drug-sensitive OVCAR8 and resistant OVCAR8/ADR
cancer cells. The novel nanoformula with a
cholanic acid-derivatized
hyaluronic acid (CAHA)
biopolymer wrapped around a sSWCNT and loaded with
doxorubicin (DOX), CAHA-sSWCNT-DOX, is much more effective in killing
drug-resistant
cancer cells compared to the free DOX and
phospholipid PEG (PL-PEG)-modified sSWCNT formula, PEG-sSWCNT-DOX. The CAHA-sSWCNT-DOX affects the viscoelastic property more than free DOX and PL-PEG-sSWCNT-DOX, which in turn allows more
drug molecules to be internalized.
Intravenous injection of CAHA-sSWCNT-DOX (12 mg/kg DOX equivalent) followed by 808 nm
laser irradiation (1 W/cm(2), 90 s) led to complete
tumor eradication in a subcutaneous OVCAR8/ADR
drug-resistant xenograft model, while free DOX alone failed to delay
tumor growth. Our newly developed CAHA-sSWCNT-DOX nanoformula, which delivers
therapeutics and acts as a sensitizer to influence
drug uptake and induce apoptosis with minimal resistance factor, provides a novel effective means of counteracting the phenomenon of multidrug resistance.